Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations (Pediatric MATCH)
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients With Tumors Harboring HRAS Genomic Alterations
Clinical Trial Information
Trial Contact: Spinelli, Jennifer; Leffin, Melissa; El-Shami, Jessica
To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with tipifarnib with advanced solid tumors (including central nervous system [CNS] tumors), lymphomas or histiocytic disorders that harbor activating genetic alterations in HRAS.
Sexes Eligible for Study - All
Ages - 12 Months to 21 Years (Child, Adult)
Accepts Healthy Volunteers - No